A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  New England Journal of Medicine

• Publication date

  2006-08-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1056/NEJMOA060467PMID 16899777
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lung Cancer

  2015cited by this paper
• Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

  2006cited by this paper
• High-resolution genomic profiles of human lung cancer.

  2005cited by this paper
• Global detection of molecular changes reveals concurrent alteration of several biological pathways in nonsmall cell lung cancer cells

  2005cited by this paper
• High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

  2005cited by this paper
• Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

  2005cited by this paper
• ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association

  2005cited by this paper
• Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy.

  2005cited by this paper
• Survival Trees for Analyzing Clinical Outcome in Lung Adenocarcinomas Based on Gene Expression Profiles: Identification of Neogenin and Diacylglycerol Kinase α Expression as Critical Factors

  2005cited by this paper
• Multidisciplinary management of lung cancer.

  2004cited by this paper
• A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.

  2004cited by this paper
• Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes.

  2004cited by this paper
• Multidisciplinary management of lung cancer.

  2004cited by this paper
• Bayesian analysis of binary prediction tree models for retrospectively sampled outcomes.

  2004cited by this paper
• Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

  2004cited by this paper
• Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633.

  2004cited by this paper
• Gene expression predictors of breast cancer outcomes.

  2003cited by this paper
• Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs

  2003cited by this paper
• Protein profiles associated with survival in lung adenocarcinoma

  2003cited by this paper
• Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction.

  2003cited by this paper
• Gene-expression profiles predict survival of patients with lung adenocarcinoma

  2002cited by this paper
• Molecular profiling of non-small cell lung cancer and correlation with disease-free survival.

  2002cited by this paper
• Prognostic factors in non-small cell lung cancer: a decade of progress.

  2002cited by this paper
• Diversity of gene expression in adenocarcinoma of the lung

  2001cited by this paper
• Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

  2001cited by this paper
• Predicting the clinical status of human breast cancer by using gene expression profiles

  2001cited by this paper
• Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author)

  2001cited by this paper
• Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer

  2000cited by this paper
• A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers.

  1999cited by this paper
• A Bayesian CART algorithm

  1998cited by this paper
• Revisions in the International System for Staging Lung Cancer.

  1997cited by this paper
• Survival in early-stage non-small cell lung cancer.

  1995cited by this paper
• Lung cancer.

  1990cited by this paper
• A new international staging system for lung cancer.

  1987cited by this paper
• The new International Staging System for Lung Cancer.

  1986cited by this paper

• OncoFlow: A Multiplexed Microfluidic Platform for Personalized Drug Sensitivity Assessment.

  2025cites this paper
• Explainable biology for improved therapies in precision medicine: AI is not enough.

  2024cites this paper
• Molecular risk factors for locoregional recurrence in resected non‐small cell lung cancer

  2023cites this paper
• Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect

  2023cites this paper
• A Comprehensive Survey on the Progress, Process, and Challenges of Lung Cancer Detection and Classification

  2022cites this paper
• Phospho-RNAseq Profiling of Extracellular mRNAs and lncRNAs.

  2021cites this paper
• Clinical significance of breast cancer susceptibility gene 1 expression in resected non-small cell lung cancer: A meta-analysis

  2021cites this paper
• Personalized drug-response prediction model for lung cancer patients using machine learning

  2020cites this paper
• LncRNA HCP5 Stimulates the Proliferation of Non-Small Cell Lung Cancer Cells by Up-Regulating Survivin Through the Down-Regulation of miR-320

  2020influential citation
• The Combination of CA125 and NSE Is Useful for Predicting Liver Metastasis of Lung Cancer

  2020cites this paper
• Creation of a Prognostic Risk Prediction Model for Lung Adenocarcinoma Based on Gene Expression, Methylation, and Clinical Characteristics

  2020cites this paper
• OTT_A_248436 3085..3091

  2020cites this paper
• Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis

  2020cites this paper
• CMAR_A_222221 1129..1134

  2020influential citation
• A Bayesian adaptive marker‐stratified design for molecularly targeted agents with customized hierarchical modeling

  2019cites this paper
• Devices for image-guided lung interventions: State-of-the-art review

  2019cites this paper
• Identificación in silico de biomarcadores transcripcionales de cáncer de pulmón

  2019cites this paper
• Genetic variants in RUNX3, AMD1 and MSRA in the methionine metabolic pathway and survival in nonsmall cell lung cancer patients

  2019cites this paper
• Phospho-sRNA-seq reveals extracellular mRNA/lncRNA fragments as potential biomarkers in human plasma

  2019cites this paper
• Phospho‐RNA‐seq: a modified small RNA‐seq method that reveals circulating mRNA and lncRNA fragments as potential biomarkers in human plasma

  2019cites this paper
• Current trends and emerging diagnostic techniques for lung cancer.

  2018cites this paper
• 3D Printing Endobronchial Models for Surgical Training and Simulation

  2018cites this paper
• Challenges in Developing Prediction Models for Multi-modal High-Throughput Biomedical Data

  2018cites this paper
• A Radiomics Signature in Preoperative Predicting Degree of Tumor Differentiation in Patients with Non-small Cell Lung Cancer.

  2018cites this paper
• Molecular Staging and Prognosis in Lung Cancer Estadificación y pronóstico molecular del cáncer de pulmón

  2018cites this paper
• Meet the new boss: lung cancer staging.

  2018cites this paper
• PRedicting Outcomes For Crohn’s dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial

  2018cites this paper
• Accurity: accurate tumor purity and ploidy inference from tumor-normal WGS data by jointly modelling somatic copy number alterations and heterozygous germline single-nucleotide-variants

  2018cites this paper
• Evaluating Common Strategies for the Efficiency of Feature Selection in the Context of Microarray Analysis

  2017cites this paper
• Tumor Microenvironment

  2017cites this paper
• Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma.

  2017cites this paper
• Correction to: MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway

  2017cites this paper
• Omic Technologies and Lung Cancer

  2017cites this paper
• MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway

  2017cites this paper
• Identification of microRNAs in acute respiratory distress syndrome based on microRNA expression profile in rats.

  2017cites this paper
• Generating a robust prediction model for stage I lung adenocarcinoma recurrence after surgical resection

  2017cites this paper
• A meta‐analysis: microRNAs’ prognostic function in patients with nonsmall cell lung cancer

  2017cites this paper
• Molecular Basis of Lung Carcinogenesis

  2017cites this paper
• Prognostic and predictive biomarkers post curative intent therapy.

  2017cites this paper
• Cancer Gene Profiling for Response Prediction.

  2016cites this paper
• A Predictive Model for Personalized Therapeutic Interventions in Non-small Cell Lung Cancer

  2016cites this paper
• Authentication: A Standard Problem or a Problem of Standards?

  2016cites this paper
• Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis

  2016cites this paper
• Two‐stage marker‐stratified clinical trial design in the presence of biomarker misclassification

  2016cites this paper
• 3 – Genetics of Lung Disease

  2016cites this paper
• PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome

  2016cites this paper
• Clinical Pharmacology: Current Topics and Case Studies

  2016cites this paper
• Reproducibility and replicability of rodent phenotyping in preclinical studies

  2016cites this paper
• Potential diagnostic and prognostic biomarkers of idiopathic pulmonary fibrosis and the impact of E2F8 in collagen 1 synthesis

  2016cites this paper
• Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

  2015cites this paper
• Lung and Mediastinal Tumors

  2015cites this paper
• Relationship between NOB1 expression and prognosis of resected non-small cell lung cancer

  2015cites this paper
• Immune biomarkers: how well do they serve prognosis in human cancers?

  2015cites this paper
• c-Myc-activated long non-coding RNA H19 downregulates miR-107 and promotes cell cycle progression of non-small cell lung cancer.

  2015cites this paper
• A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.

  2015cites this paper
• miRNA Analysis by Next-Generation Sequencing and its Prognostic Importance in Non-Small Cell Lung Cancer

  2015cites this paper
• Intrinsic cancer subtypes-next steps into personalized medicine

  2015cites this paper
• AQ2 Immune biomarkers: how well do they serve as

  2015cites this paper
• Personalized Medicine in Cancer

  2015cites this paper
• Gene Expression Profiling for Early-stage NSCLC

  2015cites this paper
• articleA gene expression signature of RAS pathway dependence predicts response to PI 3 K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

  2015cites this paper
• Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.

  2015cites this paper
• A three-gene signature and clinical outcome in esophageal squamous cell carcinoma

  2014cites this paper
• Assessing and comparing the performance of molecular diagnostic tests.

  2014cites this paper
• Biology of Human Tumors Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Speci fi c Molecular Entity

  2014cites this paper
• Evaluation of Phosphodiesterase 3A as a Biomarker and Target for a Novel Cytotoxic Agent

  2014cites this paper
• Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?

  2014cites this paper
• Cáncer de pulmón en el área sanitaria de Pontevedra: características clínicas, anatomopatológicas y factores pronósticos

  2014cites this paper
• Molecular Diagnosis of Cancer

  2014cites this paper
• Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma

  2014cites this paper
• Regulating laboratory-developed tests.

  2014cites this paper
• Long noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial-mesenchymal transition in lung cancer

  2014cites this paper
• CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes

  2014cites this paper
• Molecular Basis of Lung Cancer

  2014cites this paper
• Retraction Note to: Gene expression profiles on predicting protein interaction network and exploring of new treatments for lung cancer

  2014cites this paper
• The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence

  2014cites this paper
• Improving the Transparency of Prognosis Research: The Role of Reporting, Data Sharing, Registration, and Protocols

  2014cites this paper
• Clinical Trial Misconduct

  2014cites this paper
• Recent Questions in Responsible Conduct of Research

  2014cites this paper
• Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non–Small-Cell Lung Cancer Including Stage IA Patients

  2014cites this paper
• Cancer of the Lung: Non–Small Cell Lung Cancer and Small Cell Lung Cancer

  2014cites this paper
• Exhaled Volatile Organic Compounds as Noninvasive Early Molecular Markers in Lung Cancer: Bridging the Gap from Bench to Bedside

  2014cites this paper
• Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity

  2014cites this paper
• A three-protein signature and clinical outcome in esophageal squamous cell carcinoma

  2014cites this paper
• Integrating Radio Imaging With Gene Expressions Toward a Personalized Management of Cancer

  2014cites this paper
• RETRACTED ARTICLE: Gene expression profiles on predicting protein interaction network and exploring of new treatments for lung cancer

  2014cites this paper
• Ib期上叶肺癌纵隔淋巴结清扫方式的研究

  2013cites this paper
• A powerful Bayesian meta-analysis method to integrate multiple gene set enrichment studies

  2013cites this paper
• Evolution of Translational Omics: Lessons Learned and the Path Forward

  2013cites this paper
• Personalized Medicine: Development of a Predictive Computational Model for Personalized Therapeutic Interventions

  2013cites this paper
• The long journey of cancer biomarkers from the bench to the clinic.

  2013cites this paper
• Integration of Clinical and Genomic data : a Methodological Survey

  2013cites this paper
• Support vector machine-based nomogram predicts postoperative distant metastasis for patients with oesophageal squamous cell carcinoma

  2013cites this paper
• Současné trendy adjuvantní chemoterapie u nemalobuněčného karcinomu plic

  2013cites this paper
• Classification with minimum expected error over an uncertainty class of Gaussian distributions

  2013cites this paper
• Unravelling the mechanisms of durable control of HIV-1

  2013cites this paper
• Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: implications for personalized medicine.

  2013cites this paper
• Prognostic factors in resected lung carcinomas

  2013cites this paper
• From mutation to methylation - molecular markers in lung cancer

  2013cites this paper
• Gene expression profiling and molecular pathway analysis for the identification of early-stage lung adenocarcinoma patients at risk for early recurrence.

  2013cites this paper